allogeneic anti-GD2 KOKI DAR T-cell therapy (Sorreno Therapeutics)

N/A

Report date: 2025/01/26 17:55:23

Base Information

Drug Nameallogeneic anti-GD2 KOKI DAR T-cell therapy (Sorreno Therapeutics)
Drug Alias Nameallogeneic anti-GD2 CAR T-cell therapy (Sorreno Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionDisialoganglioside GD2 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSolid tumoursNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A